Array Biopharma Inc., of Boulder, Colo., and Pierre Fabre SA, of Castres, France, reported results from the pivotal phase III COLUMBUS trial of binimetinib plus encorafenib (bini/enco) treatment in BRAF-mutant melanoma patients at the Society for Melanoma Research meeting in Boston. Read More
XTL Biopharmaceuticals Ltd., of Raanana, Israel, said it received notice from Nasdaq that its American depositary shares (ADSs) had fallen below the $1 minimum bid price for 30 consecutive business days. Read More
Theravance Biopharma Inc., of Dublin, reported third-quarter revenue of $19.1 million, beating consensus estimates of $12.6 million, including $3.9 million in U.S. net product sales of antibiotic Vibativ (telavancin). Read More
By targeting a so-called auxiliary protein, researchers have selectively inhibited specific neural circuits whose malfunction underlies one form of epilepsy. Read More
Arrowhead Pharmaceuticals Inc. “should receive a letter from the [FDA] within 30 days that spells out what they want,” President and CEO Christopher Anzalone told BioWorld Today. Read More
COLOGNE, Germany – As the curtain closed on the 22nd annual BIO-Europe Fall meeting Wednesday, the tumultuous election news from the U.S. was the main topic of conversation among delegates. The future prospects for European biotechnology were a secondary consideration for many. Read More
The election of real estate mogul Donald Trump to the presidency of the U.S. may or may not have upended the Washington establishment, but the policy implications for the life sciences are substantial. Read More
Despite outrage over escalating drug prices, more than half the voters in California rejected Proposition 61, which was intended to cap certain drug costs at the discounted rates paid by the Department of Veterans Affairs (VA). Read More
